Literature DB >> 11939306

Frequency of the mutant MDR1 allele associated with ivermectin sensitivity in a sample population of collies from the northwestern United States.

Katrina L Mealey1, Steven A Bentjen, Denise K Waiting.   

Abstract

OBJECTIVE: To determine the frequency of the MDR1 gene mutation (polymorphism) associated with ivermectin sensitivity in a sample population of Collies in Washington and Idaho. ANIMALS: 40 healthy client-owned Collies. PROCEDURE: A blood sample (8 ml) was collected from each dog and used for RNA extraction. Reverse transcriptase was used to generate MDR1 cDNA. Polymerase chain reaction (PCR) primers were designed to amplify a 1,061-base pair region of the MDR1 gene. The PCR products were sequenced to determine whether the Collies had 0, 1, or 2 mutant alleles. Pedigrees of some dogs were available for analysis to determine relatedness of affected dogs.
RESULTS: Of the 40 Collies, 9 (22%) were homozygous for the normal allele (normal), 17 (42%) were heterozygous (carrier), and 14 (35%) were homozygous for the mutant allele (affected). Pedigree analysis revealed that some, but not all, affected dogs were related to each other within the 4 most recent generations. CONCLUSIONS AND CLINICAL RELEVANCE: A high percentage of a sample population of Collies in Washington and Idaho are affected or carriers of the mutant MDR1 allele associated with ivermectin sensitivity. A similar frequency of this mutation may be detected in dogs from other geographic areas. Pharmacologic treatment with ivermectin, loperamide, vincristine, and other drugs that are substrates of P-glycoprotein, the MDR1 gene product, may result in neurologic toxicosis in a high percentage of Collies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11939306     DOI: 10.2460/ajvr.2002.63.479

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  11 in total

1.  The role of Brugia malayi ATP-binding cassette (ABC) transporters in potentiating drug sensitivity.

Authors:  Jeffrey B Tompkins; Laurel E Stitt; Alana M Morrissette; Bernadette F Ardelli
Journal:  Parasitol Res       Date:  2011-04-15       Impact factor: 2.289

2.  The antihelminthic moxidectin enhances tonic GABA currents in rodent hippocampal pyramidal neurons.

Authors:  Jay Spampanato; Anne Gibson; F Edward Dudek
Journal:  J Neurophysiol       Date:  2018-01-24       Impact factor: 2.714

3.  Breed distribution and history of canine mdr1-1Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage.

Authors:  Mark W Neff; Kathryn R Robertson; Aaron K Wong; Noa Safra; Karl W Broman; Montgomery Slatkin; Katrina L Mealey; Niels C Pedersen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

Review 4.  Moxidectin and the avermectins: Consanguinity but not identity.

Authors:  Roger Prichard; Cécile Ménez; Anne Lespine
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-04-14       Impact factor: 4.077

Review 5.  Ivermectin: An Anthelmintic, an Insecticide, and Much More.

Authors:  Richard J Martin; Alan P Robertson; Shivani Choudhary
Journal:  Trends Parasitol       Date:  2020-11-11

Review 6.  Treatment of MDR1 mutant dogs with macrocyclic lactones.

Authors:  Joachim Geyer; Christina Janko
Journal:  Curr Pharm Biotechnol       Date:  2012-05       Impact factor: 2.837

7.  Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon.

Authors:  Michel Boussinesq; Jacques Gardon; Nathalie Gardon-Wendel; Jean-Philippe Chippaux
Journal:  Filaria J       Date:  2003-10-24

8.  Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients.

Authors:  Charles D Mackenzie; Timothy G Geary; John A Gerlach
Journal:  Filaria J       Date:  2003-10-24

9.  Frequency of canine nt230(del4) MDR1 mutation in prone pure breeds, their crosses and mongrels in Israel - insights from a worldwide comparative perspective.

Authors:  Yaron Dekel; Yossy Machluf; Aviad Stoler; Arava Aderet; Daniel Baumel; Efrat Kellerman; Yoram Plotsky; Oshrat Noked Partouche; Gal Elhalal; Izhar Ben-Shlomo; Dani Bercovich
Journal:  BMC Vet Res       Date:  2017-11-13       Impact factor: 2.741

10.  Moxidectin: a review of chemistry, pharmacokinetics and use in horses.

Authors:  Rami Cobb; Albert Boeckh
Journal:  Parasit Vectors       Date:  2009-09-25       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.